These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 21476608)
1. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. Hartrick CT; Rozek RJ CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608 [TBL] [Abstract][Full Text] [Related]
2. Tapentadol for pain: a treatment evaluation. Hartrick CT; Rodríguez Hernandez JR Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161 [TBL] [Abstract][Full Text] [Related]
3. Tapentadol - A representative of a new class of MOR-NRI analgesics. Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501 [TBL] [Abstract][Full Text] [Related]
5. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444 [TBL] [Abstract][Full Text] [Related]
6. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Frampton JE Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478 [TBL] [Abstract][Full Text] [Related]
7. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. Tzschentke TM; Christoph T; Kögel BY CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology update: tapentadol for neuropathic pain. Pierce DM; Shipstone E Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021 [TBL] [Abstract][Full Text] [Related]
9. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647 [TBL] [Abstract][Full Text] [Related]
10. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822 [TBL] [Abstract][Full Text] [Related]
12. Tapentadol-ER for the treatment of diabetic peripheral neuropathy. Games G; Hutchison A Consult Pharm; 2013 Oct; 28(10):672-5. PubMed ID: 24129223 [TBL] [Abstract][Full Text] [Related]
13. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437 [TBL] [Abstract][Full Text] [Related]
14. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Bee LA; Bannister K; Rahman W; Dickenson AH Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473 [TBL] [Abstract][Full Text] [Related]